Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic - PubMed (original) (raw)
Affiliations
- PMID: 20140817
Review
Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic
Zelig Eshhar. Curr Opin Mol Ther. 2010 Feb.
Abstract
The treatment of patients with cancer using passive vaccination with antibodies has been demonstrated to be a promising option, particularly for 'soft tumors', most likely because of their greater accessibility compared with bulky solid tumors. While effector T-cells are efficient in the rejection of large organs and foreign tissues, the wide application of tumor-specific T-cells for cancer therapy has been limited by the inherent restriction of T-cell recognition to self antigens, and the difficulty in obtaining sufficient numbers of such cells with defined specificity. Advances in gene transfer and cell therapy have enabled the genetic modification of T-cells by the ectopic expression of predefined, specific receptor genes that redirect such 'designer cells' to any target of interest. This review discusses two approaches to applying redirected T-cells for adoptive cancer immunotherapy: the 'T-body' approach, which employs chimeric receptors with tumor-specific antibody-derived specificity, and the use of transgenes encoding tumor-specific T-cell receptors. Particular emphasis is placed on recent attempts using these approaches in the treatment of patients with cancer.
Similar articles
- The T-body approach: redirecting T cells with antibody specificity.
Eshhar Z. Eshhar Z. Handb Exp Pharmacol. 2008;(181):329-42. doi: 10.1007/978-3-540-73259-4_14. Handb Exp Pharmacol. 2008. PMID: 18071952 Review. - Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
Berry LJ, Moeller M, Darcy PK. Berry LJ, et al. Tissue Antigens. 2009 Oct;74(4):277-89. doi: 10.1111/j.1399-0039.2009.01336.x. Tissue Antigens. 2009. PMID: 19775368 Review. - Genetic redirection of T cells for cancer therapy.
Westwood JA, Kershaw MH. Westwood JA, et al. J Leukoc Biol. 2010 May;87(5):791-803. doi: 10.1189/jlb.1209824. Epub 2010 Feb 23. J Leukoc Biol. 2010. PMID: 20179152 Review. - Breast cancer immunotherapy.
Zhou J, Zhong Y. Zhou J, et al. Cell Mol Immunol. 2004 Aug;1(4):247-55. Cell Mol Immunol. 2004. PMID: 16225767 Review. - Antigen choice in adoptive T-cell therapy of cancer.
Offringa R. Offringa R. Curr Opin Immunol. 2009 Apr;21(2):190-9. doi: 10.1016/j.coi.2009.02.006. Epub 2009 Mar 16. Curr Opin Immunol. 2009. PMID: 19297140 Review.
Cited by
- Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.
Sauerer T, Albrecht L, Sievers NM, Gerer KF, Hoyer S, Dörrie J, Schaft N. Sauerer T, et al. Methods Mol Biol. 2024;2786:219-235. doi: 10.1007/978-1-0716-3770-8_10. Methods Mol Biol. 2024. PMID: 38814397 - Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?
Fan J, Shang D, Han B, Song J, Chen H, Yang JM. Fan J, et al. Theranostics. 2018 Nov 10;8(20):5784-5800. doi: 10.7150/thno.29035. eCollection 2018. Theranostics. 2018. PMID: 30555581 Free PMC article. Review. - Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.
Riaz IB, Zahid U, Kamal MU, Husnain M, McBride A, Hua A, Hamadani AA, George L, Zeeshan A, Sipra QR, Raina A, Rahman B, Puvvada S, Anwer F. Riaz IB, et al. Immunotherapy. 2017 Sep;9(12):979-993. doi: 10.2217/imt-2017-0062. Immunotherapy. 2017. PMID: 28971751 Free PMC article. Review. - Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery.
Katz SC, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ, Boutros C, Hanna N, Junghans RP. Katz SC, et al. Cancer Gene Ther. 2016 May;23(5):142-8. doi: 10.1038/cgt.2016.14. Epub 2016 Apr 15. Cancer Gene Ther. 2016. PMID: 27080226 Free PMC article. - IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells.
Andrijauskaite K, Suriano S, Cloud CA, Li M, Kesarwani P, Stefanik LS, Moxley KM, Salem ML, Garrett-Mayer E, Paulos CM, Mehrotra S, Kochenderfer JN, Cole DJ, Rubinstein MP. Andrijauskaite K, et al. Cancer Gene Ther. 2015 Jul;22(7):360-7. doi: 10.1038/cgt.2015.28. Epub 2015 Jul 17. Cancer Gene Ther. 2015. PMID: 26182912 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources